NPS Pharmaceuticals to Report 2012 Financial Results

  NPS Pharmaceuticals to Report 2012 Financial Results

Business Wire

BEDMINSTER, N.J. -- February 13, 2013

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report
its 2012 financial results on Thursday, February 21, 2013 at approximately
4:00 p.m. ET. The press release will be followed by a conference call and
webcast at 4:30 p.m. ET.

To participate in the conference call, dial (866) 783-2137 and use passcode
99534128. International callers may dial (857) 350-1596, using the same
passcode. In addition, a live audio of the conference call will be available
over the Internet. Interested parties can access the event through the
investors’ calendar of events page on the NPS website,
http://www.npsp.com/calendar.

If you are unable to participate in the live call, a replay will be available
at (888) 286-8010, with passcode 99734684 until midnight ET, March 7, 2013.
International callers may access the replay by dialing (617) 801-6888, using
the same passcode. The webcast will also be available through the NPS website
for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan
products to patients with rare disorders and few, if any, therapeutic options.
The company’s lead product, Gattex^® 0.05 mg/kg/d (Teduglutide [rDNA origin])
for Injection is FDA-approved for the treatment of adult patients with short
bowel syndrome (SBS) who are dependent on parenteral support. NPS is also
developing Natpara^® (rhPTH[1-84]) for the treatment of adult
hypoparathyroidism and expects to submit its Biologic License Application
(BLA) to the FDA in mid-2013. NPS's earlier stage pipeline includes two
calcilytic compounds, NPSP790 and NPSP795, with potential application in rare
disorders involving increased calcium receptor activity, such as autosomal
dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its
proprietary programs with a royalty-based portfolio of products and product
candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen
Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH.

Contact:

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335
 
Press spacebar to pause and continue. Press esc to stop.